This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. LCLs and a good correlation between DNA hypomethylation and repeat length. In addition, DUX4-fl levels can be manipulated using epigenetic drugs as in myocytes, suggesting that some epigenetic pathways regulating DUX4-fl in myocytes are maintained in LCLs. Overall, these FSHD LCLs provide an alternative cellular model in which to study many aspects of D4Z4, DUX4, and FSHD gene regulation in a background of low genetic variation. Significantly, these non-adherent immortal LCLs
Introduction
Facioscapulohumeral muscular dystrophy (FSHD), affecting ~1:7,500-15,000 individuals, is the most prevalent muscular dystrophy that indiscriminately afflicts children and adults of all ages and both genders [1] [2] [3] [4] [5] . All forms of FSHD are genetically and epigenetically linked to the chromosome 4q35 D4Z4 macrosatellite array, with the interplay between these factors accounting for much of the high variability in disease penetrance and severity characteristic of the disease [1, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . The predominant form of the disease, FSHD1 (OMIM 158900), represents >95% of reported cases and results from large DNA deletions within the 4q35 D4Z4 repeat array [16, 17] . Healthy, genetically unaffected individuals are typically defined as having more than 10 D4Z4 repeat units (RUs) on both 4q chromosome arms (generally [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] RUs and as high as 120 RUs per array [18, 19] ), whereas individuals with genetic FSHD1 have a contracted D4Z4 array in the range of 1 to 10 D4Z4 RUs on one 4q chromosome arm, consistent with an autosomal dominant mode of inheritance ( Fig. 1 ) [20] . These polymorphic FSHD1-sized D4Z4
contractions are not sufficient for pathogenesis; development of FSHD also requires a disease permissive allele of the chromosome 4q subtelomere (4A) in cis with the contracted array [19, [21] [22] [23] . FSHD2 (OMIM 158901), the far less common form of FSHD, presents with similar clinical features as FSHD1, but is caused by unlinked mutations in genes encoding chromatin regulatory proteins [7, 8, 24, 25] . However, FSHD2 is also genetically linked to the 4q35 array by the requirement of at least one permissive 4A-type subtelomere and a specific range of D4Z4 RUs (~11-28 RUs) in order to develop disease [7, 23] . Thus, with these genetic requirements, FSHD2 is considered a digenic disease [8, 25] .
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Despite the clear genetic distinctions between these two forms of FSHD, the effects on D4Z4 chromatin are quite similar. In FSHD1, the 4q35 deletions result in the loss of regulatory heterochromatin that significantly alters the local epigenetic landscape of the contracted allele and is characterized by allele-specific DNA hypomethylation [12, [26] [27] [28] [29] [30] . FSHD2 mutations reside in the genes encoding the epigenetic machinery responsible for establishing and maintaining repression of the D4Z4 arrays; therefore, FSHD2 is characterized by DNA hypomethylation of both 4q35 D4Z4 arrays and often both 10q26 arrays as well [7, 8, 25] . Thus, although epigenetic dysregulation is characteristic of FSHD in general, FSHD1 and FSHD2 subjects can be distinguished from each other and even individually diagnosed based on the DNA methylation profiles of the 4q35 D4Z4 arrays and disease permissive alleles [11, 31, 32] . In addition, some FSHD1 subjects may also have FSHD2-type mutations, with the combined effect presenting as a very severe form of FSHD, thus characterizing these genes as modifiers of disease severity [9] . To date, there have been two FSHD1 modifier genes identified, SMCHD1 and DNMT3B [8, 25] , both of which encode epigenetic regulator proteins, further highlighting the importance of the 4q35 epigenetic status with respect to disease presentation.
In both forms of FSHD, chromatin de-repression at the 4q35 D4Z4 macrosatellite has similar downstream molecular consequences, resulting in the aberrant expression of a pathogenic isoform of the DUX4 (double homeobox 4) gene, DUX4-fl, in skeletal muscle [33] [34, 35] [ 15, 23, 26, [35] [36] [37] [38] . Each D4Z4 RU encodes a copy of DUX4 [33] ; however, only DUX4-fl produced from the distal-most 4q35 D4Z4 RU is stably expressed in FSHD.
This is due to an array-distal polyadenylation signal (PAS) in the noncoding exon 3 of
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DUX4, which is only present in permissive 4q alleles (termed 4qA) [23, 35] . This PAS is required to stably express DUX4 mRNAs in somatic cells and is essential for developing both forms of FSHD. However, the DUX4 PAS is absent from about half of the 4q chromosomes (4qB alleles) in the human population. These non-permissive 4qB chromosomes lack exon 3 of the DUX4 gene and are therefore unable to generate polyadenylated DUX4 mRNA in somatic cells, supporting the requirement for stable DUX4 expression in the development of FSHD [21, 23, 35, 39, 40] . Interestingly, the highly homologous chromosome 10q26 D4Z4 arrays have the A-type exon 3 sequence distal to the array; however, the putative DUX4 PAS is a sequence variant that does not signal polyadenylation, thus explaining why D4Z4 contractions on chromosome 10 are not associated with FSHD [21, 23, 39] .
With the identification of DUX4 as the key pathogenic gene in FSHD, the field is now engaged in designing DUX4-targeted therapies [23, 33, 35, 41, 42] . Therapies can also be targeted upstream of DUX4 expression, as the epigenetic disruption at the FSHD locus is a major determinant in disease presentation and progression. In addition, there are multiple genetic and epigenetic modifiers of FSHD severity, which provide additional therapeutic targets [7, 9, 12, 25, 36, 43] . However, the fundamental nature of FSHD presents several obstacles to traditional drug development and screening (e.g., DUX4 is a primate-specific gene expressed at very low levels primarily in differentiated FSHD skeletal myocytes, which are not amenable to high-throughput screening [35] [36] [37] [20, [44] [45] [46] [47] [48] . The present study includes an updated genetic and molecular characterization of 56 LCLs from six families in the Utah cohort; thus, the availability of these LCLs, along with 58 LCLs not known to be linked to the Utah cohort (although distant linkage has not been excluded), may provide a wealth of new information with respect to the role of familial genetic background and the identification of factors that act as disease modifiers [48] . Importantly, despite being immortalized and non-myogenic, these cells represent useful models of FSHD-dependent DUX4 expression that can be therapeutically targeted and manipulated in a format suitable for high-throughput drug screening.
Patients and methods

Subjects and cells
All cells used in this study are Epstein-Barr virus-transformed B-LCLs generated in the laboratory of Stephen J. Jacobsen at the University of California School of Medicine, La Jolla, CA, USA and subjected to the same process for immortalization. LCLs were transferred to the NIGMS Human Genetic Cell Repository at the Coriell Institute for 
D4Z4 deletion analysis
Genomic Southern blotting to identify subjects possessing 4q35 deletions was performed as described [49] , and following personal communication with Dr. Yukiko Hayashi.
Briefly, 7.5 g of LCL genomic DNA was digested overnight with either EcoRI or both
EcoRI and AvrII (New England Bioloabs), electrophoresed through a 0.3% agarose TAE gel for 36 h at 12 mAmps, denatured, and transferred to a nylon membrane. Blots were probed with radiolabeled p13E-11 fragment [16] and assessed for EcoRI restriction fragments that decreased in size by 3.2 kb when combined with AvrII digestions, indicating the particular fragment was from chromosome 4q [50, 51] . AvrII is an isoschizomer of BlnI, the enzyme traditionally used for FSHD1 diagnosis to distinguish 4q35 D4Z4 arrays from the BlnI-sensitive chromosome 10q26 D4Z4 arrays.
DNA methylation analysis
The DNA methylation status of the 4q35 D4Z4 array was determined by bisulfite sequencing (BSS) analysis. BSS analysis of the 4qA distal D4Z4 repeat unit was performed on genomic DNAs isolated from LCLs, as described [12, 31] . BSS analysis for the distal D4Z4 repeat unit containing a B-type subtelomeric region was performed using the MetB-For and MetB-Rev PCR primers [30] . PCR products were cloned into the pGEM-T Easy vector (Promega) for sequencing and analyzed using web-based analysis software BISMA (http://biochem.jacobs-university.de/BDPC/BISMA/) [52] with the default parameters.
Chromosome 4q trace by Simple Tandem Repeat analysis (4qSTR analysis)
In order to confirm the position of each cell line in its family pedigree and to trace inheritance of 4q D4Z4 repeats, PCR-based 4qSTR analysis was performed using three STR markers: D4S2930 and D4S1523 that have high heterozygosity and most proximity to D4Z4 (900kb and 500kb, respectively), and D4F104S1/SSLP (4q/10q STR marker) [53] (https://www.urmc.rochester.edu/fields-center.aspx). For Family36, D4S1652 was also analyzed to further identify parental origin of 4q. Gender of each sample was also confirmed by STR analysis of amelogenin [54] .
Haplotyping and polyadenylation signal (PAS) analysis
Standard genomic PCR was performed on non-converted LCL DNA and about 30% of each PCR reaction was run on 2% agarose gels to identify the 4qA, 4qA-L, and 4qB chromosomes, as described [23] . The rest of the 4A and 4AL PCR fragments were purified with a PCR purification kit (Qiagen) and used for direct DNA sequencing to confirm PAS and D4F104S1/SSLP haplotypes. Specific 4q and 10q haplotypes were identified and assigned as described [22, 40] .
Gene expression analysis
Total RNA was prepared from each cell line using TRIzol (ThermoFisher), as per manufacturer's instructions, followed by clean-up using the RNeasy mini kit (Qiagen).
First strand cDNA was generated from 2 μg total RNA using SuperScript III reverse transcriptase and Oligo (dT) 16 primer at 55C for 1 hr. DUX4 expression was analyzed using nested PCR. taken at 86C for 10 sec. Expression of DUX4 target genes was analyzed by qPCR using 5 to 10 ng cDNA, as described [55] . Expression of all genes was normalized to 18S
rRNA, analyzed by qPCR using 5 ng of cDNA. All oligonucleotide primer sequences for DUX4, downstream targets, and 18S rRNA are previously reported [37] . Some DUX4-fl qPCR products were purified with a PCR purification kit (Qiagen) and used for direct DNA sequencing to confirm haplotype.
Results
3.1
Genetic characterization of FSHD1 in cohorts of LCLs.
We Family 36, the contracted arrays were found on non-permissive 4qB chromosomes, with no PAS detected, and were therefore genetically characterized as healthy controls [39] .
Interestingly, none of these three subjects was clinically classified as FSHD; however, two other members of Family 36, GM16348 and GM16351, who were clinically diagnosed with FSHD, were confirmed to have FSHD1-sized D4Z4 contractions (16kb)
on FSHD-permissive 4qA chromosomes. Thus, this one family illustrates the requirement for both a contracted 4q allele and the permissive 4qA exon 3 PAS for developing FSHD. The remaining 48 LCLs did not meet these FSHD1 genetic criteria and were therefore classified as healthy controls, bringing the total number of control LCLs to 51.
FSHD1 displays an autosomal dominant mode of inheritance with incomplete and variable penetrance [13, 20] . Including the FSHD1 genetic diagnosis for each subject on criteria were derived from subjects that did not show any clinical signs of FSHD at the time of their neuromuscular examination and blood donation, suggesting that these subjects are FSHD1 carriers. In addition, the FSHD1 EcoRI/AvrII deletion sizes (22-33kb or 6-9RU) for each of these subjects is within the range reported for asymptomatic FSHD1 [11, 12, 14, 36] ; therefore, these 8 subjects are considered in this study to be asymptomatic. It is possible that these subjects were examined prior to developing clinical FSHD, which is typically diagnosed in males by age 20 and females by age 30.
Fortunately, the identifying information provided with these samples allowed us to determine the age, within ~4 years, at which each designated asymptomatic subject was analyzed. Six of the subjects were >24 years old, with the oldest being >65 years, and two of the subjects from Family 11 (GM16416 and GM16430), both brothers, were <20 years old. The designation for these two youngest asymptomatic subjects raises the concern that they had yet to manifest noticeable symptoms. However, these brothers have two FSHD-affected siblings who were also <20 years old, indicating that FSHD can present at a young age in this family. Interestingly, among these four genetically FSHD1
siblings, the two affected subjects inherited the same nonpathogenic chromosome from their mother while the two asymptomatic subjects inherited the other nonpathogenic maternal chromosome (Figure 3 ), suggesting the nonpathogenic chromosome 4q allele may be contributing to disease presentation. Overall, the 8 asymptomatic LCLs in this study may prove to be informative in the future identification of disease modifiers, although caution should always be used in the interpretation of data from asymptomatic lines, particularly from younger subjects.
3.2
Correlation between DNA methylation levels and 4q35 D4Z4 repeat length in FSHD1 LCLs.
FSHD is ultimately caused by the disruption of epigenetic regulation governing the chromosome 4q35 D4Z4 macrosatellite array, combined with an FSHD-permissive 4q35 PAS, resulting in the pathogenic expression of the DUX4 gene [15, 26, 35, 57] . In FSHD1, the epigenetic disruption is caused by the loss of large regions of regulatory heterochromatin. However, it is well established that certain FSHD1-sized deletions (6-10 D4Z4 RUs) can exist in different epigenetic states that correlate with clinical presentation [11, 12, 32] . In addition, genetic mutations in epigenetic modifiers of the D4Z4 array, typical of FSHD2, can also affect the epigenetic status and clinical manifestation of disease in FSHD1 subjects [9, 25] . Although FSHD is a myopathy, the epigenetic status of the disease locus is similar between myogenic cells and peripheral blood leukocytes isolated from the same individual [26, 31] ; it is not known if immortalized LCLs similarly maintain the epigenetic status of this locus in the cells from which they were derived. Studies assessing global DNA methylation levels in LCLs compared with primary blood cells have reported both similarities and differences, thus necessitating caution in the interpretation of epigenetic profiles from LCLs [58] [59] [60] .
Therefore, in addition to screening for FSHD1-sized deletions, we characterized the epigenetic status of this cohort of cells by assaying the DNA methylation levels of the region using FSHD diagnostic bisulfite sequencing (BSS) [12, 31] (Figs. A.2 and A. 3).
Genomic DNA isolated from primary cells, saliva, or peripheral blood leukocytes of FSHD1 subjects displays <35% DNA methylation on the distal D4Z4 RU of the contracted 4qA allele when assayed using our chromosome 4qA-specific BSS assay [12, 31] . BSS analysis of FSHD1 LCLs revealed that 42/63 had levels of DNA hypomethylation considered diagnostic for FSHD1 (<35% methylation) ( who had yet to show any symptoms of FSHD despite ~5% DNA methylation in her LCLs.
Since the D4Z4 deletion is the same within each family, this lack of concordance between DNA methylation levels and disease manifestation suggests the presence of a mutation in a modifier gene or differences in other underlying genetic conditions that could account for this, such as overall D4Z4 content.
In contrast to the FSHD1 LCLs, none of the cell lines derived from healthy subjects displayed FSHD1 levels of DNA hypomethylation (0/51; n=44 hypermethylated >35% and n=7 no 4qA BSS product). However, 3 LCLs from healthy members of Family 36 (GM16349, GM16350, GM16352) contained contracted 4q35 D4Z4 arrays with non-permissive 4qB alleles (Fig. 6 , Table A.1). Since all six members of this family had at least 1 4qB allele, this family provided an opportunity to investigate the epigenetics of 4qB D4Z4 arrays. We performed 4qB-specific BSS on the 6 LCLs from Family 36 ( Fig. A.2 ) and found that the 3 healthy LCLs with contracted 4qB alleles displayed FSHD1-like levels of DNA hypomethylation (GM16349, Q1=7.1%; GM16350, Q1=0.0%; GM16352, Q1=0.0%) as compared with the non-contracted 4qB alleles with healthy levels of DNA methylation. This data supports the hypothesis that the physical removal of heterochromatin at D4Z4 arrays causes the epigenetic disruption in FSHD1 [15, 26, 28, 57] . In addition, this data provides further support for the unifying model for FSHD [23] , again confirming that a 4q35 D4Z4 contraction alone is not causal for FSHD, but requires a permissive 4qA subtelomere in cis to cause disease [39] .
We next sought to investigate the potential for these FSHD1 cell lines to possess FSHD2-type modifier mutations. Since these mutations result in hypomethylation of both alleles at 4q and 10q [9, 25] , we analyzed all FSHD1 LCLs using our D4Z4 5' BSS assay that analyzes the methylation status of all 4q and 10q D4Z4 RUs [31] . For each LCL, we found large differences in DNA methylation among all 4q and 10q D4Z4 RUs (Table A. 1), strongly suggesting that these subjects do not have known FSHD2-type modifier mutations, although we cannot rule out that the immortalization procedure and/or culturing conditions and selection may play a role in these epigenetic differences.
While a comprehensive search for modifier mutations in SMCHD1, DNMT3B, and elsewhere in the genome is beyond the scope of this study, this cohort of cell lines with appropriate family controls will be useful for addressing these types of questions.
Overall, we conclude that many, but not all, LCLs exhibit the appropriate healthy or FSHD1 DNA methylation profiles, and that this large cohort displays genetic and epigenetic characteristics that may be useful for investigating certain lines of inquiry pertinent to FSHD.
FSHD1 LCLs display robust and variable expression of DUX4-fl, which
correlates with expression of DUX4-FL target genes. To further assess the utility of these cells, we performed targeted gene expression analysis. The loss of transcriptional repression at the disease locus in FSHD results in the aberrant stable expression of the pathogenic DUX4-fl mRNA in skeletal muscle, due in part to the presence of two DUX4 myogenic enhancers [37] . Although LCLs are not myogenic, DUX4-fl expression has also been reported in non-myogenic cells [35] . Therefore, we analyzed DUX4-fl mRNA expression by qRT-PCR in all cell lines (Fig. 9 ). We readily detected robust levels of DUX4-fl mRNA in all 61 of the 4A161 contracted FSHD1 LCLs; however, the relative expression levels were highly variable within families and across the entire cohort, displaying a nearly 3000-fold range among all FSHD1 samples (Table 1) . In contrast,
DUX4-fl expression, when reliably detected at all, was generally very low in the healthy
LCLs (Table 1) Interestingly, as with FSHD myocytes [12] , cells from asymptomatic subjects (GM16254 and GM16425) are readily inducible and appear epigenetically poised to express DUX4-fl.
Since ADC can induce MyoD expression in non-myogenic cell types [68, 69] and DUX4-fl is regulated in part by myogenic factors, we assayed levels of MyoD and Myogenin in these LCLs; however, these genes were not induced by the drug treatment (data not shown). We conclude that the epigenetic regulation of DUX4-fl expression and repression is maintained in the LCLs.
Family 33
The analysis of Family 33 (Fig. 7 , Table 1 from asymptomatic subjects), and 7 healthy (2 from unaffected spouses). Thus, both 6RU and 9RU are independently associated with clinically described FSHD; however, only the 9RU chromosome was found in cell lines from asymptomatic subjects, consistent with the reported asymptomatic range of D4Z4 RUs [11, 12] . In addition, the three asymptomatic subjects were all >35 years of age at the time of their clinical evaluation, with one subject being >65 years old, supporting the classification of these subjects as asymptomatic. The 9RU chromosome in this family is particularly interesting because it has the 4qA166 haplotype, which is typically described in the literature as nonpermissive despite having an exon 3 PAS. We confirmed the presence of the PAS and, importantly, the expression of 4A166-type polyadenylated DUX4-fl mRNA in all 9RU cell lines by sequencing the RT-PCR product (Fig A.5 ) [35] . Interestingly, two of 
Discussion
The goal of this study was to perform an initial characterization of 114 LCLs long held out of circulation due to a lack of characterization, that would allow these valuable resources to be made freely available to the FSHD community through the NIGMS Human Genetic Cell Repository at the CIMR repository, where they have been held in cryostorage. This study does not represent a complete characterization of the cell lines;
for example, determining the sizes of both 4q and 10q D4Z4 arrays for each cell line or the genetic status of SMCHD1, mutations in which can be causal for FSHD2 and modify severity of FSHD1, were beyond our capabilities and outside the scope of this study [8, 9, 11] . Because the original clinical samples were collected prior to genetic testing for FSHD, we decided, in consultation with officials at CIMR, to confirm the identity of each cell line with respect to the pedigree, identify those with FSHD1-sized deletions or FSHD2-type DNA hypomethylation, determine 4q and 10q SSLPs and subtelomere haplotypes, and assess the presence or absence of an exon 3 PAS. We have successfully completed this analysis for all LCLs and provided the information to CIMR, thus making these cells immediately available to the research community through their online catalog.
One notable omission for these LCLs is information on the clinical characteristics, specific methods for evaluation, and specific diagnostic criteria used for each of the individual subjects from which they were derived. Multiple clinicians across the United
States examined these subjects and their family members, and ultimately >600 clinical samples were obtained from at least 36 families, with numerous subjects across generations clinically diagnosed with FSHD; however, many samples were lost over time, some subjects were not available for reconsent, and most of the specific clinician notes were lost or destroyed. For the samples that remained, the only clinical information available was the final clinical assessment of "FSHD"; the specific measurements and criteria for each individual (e.g., which muscles were affected, clinical severity, or level of weakness) are not known. However, an FSHD study performed by Dr. Jacobsen and colleagues, who obtained the Utah samples described in our current study and published soon thereafter, describes the clinical assessment used for FSHD subjects [44] . The criteria for FSHD were: 1) inheritance consistent with autosomal dominant genetics, 2) muscle weakness of at least one of several specific muscles of the face and shoulder girdle, and 3) muscle atrophy by the age of 20 years in at least one affected family member [44] . When matched with our blinded genetic testing, the original clinical diagnosis for FSHD was 12/12 with respect to families (all are, in fact, now known to be genetically FSHD families) and five families (2, 7, 12, 18, and 36) had a 100% match between the clinical and our genetic diagnosis for healthy and FSHD. Out of a total of 63 genetically defined FSHD1 subjects, 55 showed clinical FSHD and 8 are designated as asymptomatic (lacking clinical symptoms at the time of their assessment). We feel that the designation of asymptomatic is accurate, since these 8 subjects were examined by neurologists specifically looking for signs of clinical FSHD in families affected by the disease. This information, as with all FSHD asymptomatic or non-manifesting diagnoses, comes with the caveat that these subjects may have developed FSHD at a later time in their lives. Interestingly, 5 subjects (GM16290, GM16299, GM16322, GM16324, and GM16431) clinically characterized as FSHD were found not to contain an FSHD1-sized deletion. Unfortunately, in the absence of more detailed notes we can only speculate on the reasons for this discrepancy. However, since these subjects represent 4 different families (Family 4, 6, 11, and 32) not known to be related and all exhibit DNA methylation levels well within the range for healthy subjects, these cases likely represent over-interpretation of clinical signs. Alternatively, one or more of these could represent clinical mis-classification of a neuromuscular disease phenocopy of FSHD, but a second rare disorder spontaneously arising in even one of the families is highly unlikely. Now that nearly 30 years has passed, a potential follow-up study of all of these subjects would be extremely interesting and informative.
In addition to the minimal information required to make these LCLs available, we also collected data that would be important and useful for making decisions on which cell lines to use for different lines of investigation relevant to FSHD. As DUX4-fl expression in skeletal muscle is the key pathogenic consequence of the epigenetic disruption in FSHD, it stands to reason that DUX4-fl expression is typically and best studied in myogenic cells. follow-up study, but a knowledge of these differences is important for the planning of future experiments.
Conclusions
We have provided a preliminary genetic and molecular characterization of 114 LCLs from 12 FSHD1 affected families, enabling these cell lines to become publicly available for use by the FSHD field. We have also provided additional evidence that this cohort of cells will be a valuable resource for investigating many aspects of gene expression and regulation in FSHD. We recognize that FSHD is a muscle disease and investigating The FSH Society initiated the project and facilitated the work through its completion.
The funders played no role in the data analysis or interpretation. 
